Compare AMPG & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AMPG | TENX |
|---|---|---|
| Founded | 2002 | 1967 |
| Country | United States | United States |
| Employees | 47 | N/A |
| Industry | Telecommunications Equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Telecommunications | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 51.7M | 56.2M |
| IPO Year | N/A | 2001 |
| Metric | AMPG | TENX |
|---|---|---|
| Price | $2.20 | $11.89 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 3 |
| Target Price | $7.00 | ★ $29.67 |
| AVG Volume (30 Days) | 447.6K | ★ 588.5K |
| Earning Date | 05-14-2026 | 05-15-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $102.41 | N/A |
| Revenue Next Year | $20.00 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $1.64 | $5.34 |
| 52 Week High | $4.89 | $18.38 |
| Indicator | AMPG | TENX |
|---|---|---|
| Relative Strength Index (RSI) | 54.42 | 37.38 |
| Support Level | $1.81 | $10.83 |
| Resistance Level | $2.83 | $14.15 |
| Average True Range (ATR) | 0.12 | 0.95 |
| MACD | 0.06 | -0.27 |
| Stochastic Oscillator | 72.92 | 1.23 |
AmpliTech Group Inc designs, develops, engineers, and assembles micro-wave component-based amplifiers that meet individual customer specifications. It operates in two segments: the manufacturing and engineering segment. The products of the company consist of RF amplifiers & related subsystems, operating at multiple frequencies from 50kHz to 44GHz, including Low Noise Amplifiers, Medium Power Amplifiers, cryogenic amplifiers, and custom assemblies. The company also offers non-recurring engineering services on a project-by-project basis, for a predetermined fixed contractual amount, or on a time-plus-material basis. It also operates as a manufacturer, & distributor of cryogenic microwave amplifiers, RF designs, & applications for Wireless Networks & the future of Wireless Communication.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.